All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
QuANTUM-First: Efficacy analysis in newly diagnosed FLT3-ITD-positive AML
|
An exploratory analysis from QuANTUM-First (NCT02668653), a phase III study of quizartinib plus chemotherapy in patients with newly diagnosed FLT3-internal tandem duplication (ITD)-positive acute myeloid leukemia (AML) who received continuation therapy, was presented at the European Hematology Association 2024 Hybrid Congress by Mikkael Sekeres.1 |
| Key learnings1 |
| At a median follow-up of 39.2 months, median overall survival (OS) was not reached in either the quizartinib (n = 116) or placebo arms (n = 92) (hazard ratio [HR], 0.683; 95% confidence interval [CI], 0.395–1.183). However, at 48 months the OS rate was numerically higher for quizartinib (76.3%) vs placebo (67.9%). |
| From baseline to 36 months, a higher relapse-free survival (RFS) rate was observed in the quizartinib arm. However, in the long-term, median RFS was not reached in the placebo arm and was 48.6 months with quizartinib. |
| A higher proportion of patients (71%) in the quizartinib arm proceeded to continuation therapy after allogenic-hematopoietic stem cell transplant (allo-HSCT) vs placebo (55%). |
| In patients who did not receive allo-HSCT, there was an OS benefit in those treated with quizartinib, with a 60% reduction in the risk of death compared with placebo. |
| These findings support the use of quizartinib throughout the treatment regimen in patients with ND FLT3-mutated AML and suggest that implementation of measurable residual disease in future studies may help identify patients who will receive the most benefit from treatment with quizartinib. |
- Sekeres M. QuANTUM-First: Efficacy in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication–positive (FLT3-ITD+) acute myeloid leukemia (AML) who received continuation therapy. Oral abstract #S142. Presented at: European Hematology Association 2024 Hybrid Congress. Jun 13–16, 2024; Madrid, ES .
Your opinion matters
11 votes - 11 days left ...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox